What is HC Wainwright’s Estimate for INTS FY2026 Earnings?

Intensity Therapeutics Inc. (NASDAQ:INTS – Free Report) – Equities research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Intensity Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($4.48) per share for the year, down from their prior estimate of ($1.88). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Intensity Therapeutics’ Q4 2026 earnings at ($1.28) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.43) EPS, Q4 2027 earnings at ($0.49) EPS and FY2027 earnings at ($1.67) EPS.

A number of other research analysts also recently commented on the stock. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.00.

Get Our Latest Report on INTS

Intensity Therapeutics Price Performance

NASDAQ:INTS opened at $3.28 on Tuesday. The company has a quick ratio of 3.68, a current ratio of 3.68 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 1-year low of $2.80 and a 1-year high of $15.00. The company has a 50-day moving average of $3.57 and a 200 day moving average of $5.00.

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.10).

Top Intensity Therapeutics Stories

Here are a few of the latest stories about INTS:

  • Positive Sentiment: Brookline Capital Markets raised its long-range EPS forecasts for 2029 and 2030, while HC Wainwright kept its Buy rating and $7 target. These upbeat views are counterbalanced by lower estimates for nearer years. MarketBeat Intensity Therapeutics coverage
  • Neutral Sentiment: A short-interest update reported zero shares sold short and zero days to cover, indicating no reported short position that would clearly point to either short-squeeze potential or meaningful short-selling pressure. MarketBeat Intensity Therapeutics coverage
  • Negative Sentiment: HC Wainwright cut its 2026 and 2027 EPS forecasts, including lowering its 2026 estimate to a loss of $4.48 per share from $1.88 and its 2027 estimate to a loss of $1.67 from $0.92. Brookline also reduced its 2026 and 2027 forecasts and lowered its 2028 estimate. The broader revisions point to greater projected losses in coming periods, which may weigh on investor expectations. MarketBeat Intensity Therapeutics coverage

Intensity Therapeutics Company Profile

(Get Free Report)

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer. The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.

Featured Articles

Earnings History and Estimates for Intensity Therapeutics (NASDAQ:INTS)

Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.